Hypereosinophilic syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hypereosinophilic syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Access to Mepolizumab for Patients with Hypereosinophilic Syndrome https://clinicaltrials.eu/trial/access-to-mepolizumab-for-patients-with-hypereosinophilic-syndrome/ Wed, 29 Apr 2026 15:01:18 +0000 https://clinicaltrials.eu/trial/access-to-mepolizumab-for-patients-with-hypereosinophilic-syndrome/ This clinical trial is focused on providing access to a treatment for individuals with Hypereosinophilic Syndrome (HES). HES is a condition characterized by an abnormally high number of eosinophils, a type of white blood cell, which can lead to damage in various organs. The treatment being studied is called Mepolizumab, which is administered as a solution for injection under the skin. Mepolizumab is designed to help manage the symptoms of HES by targeting and reducing the number of eosinophils in the body.

The purpose of this study is to offer expanded access to Mepolizumab for patients who have a significant medical need and for whom the potential benefits of the treatment outweigh the risks. This program is available in certain countries where regulatory authorities permit it. The study involves regular administration of Mepolizumab, and participants will be monitored by healthcare professionals to ensure their safety and well-being throughout the treatment period.

Participants in this study will receive Mepolizumab injections and will be closely observed by their healthcare provider. The healthcare provider will use their clinical judgment to determine if Mepolizumab is suitable for the patient, based on the information provided in the Investigator’s Brochure, which contains detailed information about the drug. The study aims to ensure that patients with HES who have not responded to other treatments can access Mepolizumab as a potential option for managing their condition.

]]> A Study of Depemokimab and Prednisolone in Adults with Hypereosinophilic Syndrome (HES) https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-depemokimab-and-prednisolone-for-adults-with-hypereosinophilic-syndrome-hes/ Wed, 29 Apr 2026 15:01:07 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-depemokimab-and-prednisolone-for-adults-with-hypereosinophilic-syndrome-hes/ This study focuses on people with Hypereosinophilic Syndrome (HES), a rare blood condition where there are too many white blood cells called eosinophils in the blood and tissues. These elevated levels can cause damage to various organs in the body. The study will test a new medication called depemokimab, which is given as an injection under the skin, along with standard treatments that may include prednisolone tablets.

The purpose of this research is to determine if depemokimab is effective in controlling HES when compared to placebo in people who are already receiving standard care. The study will last for 52 weeks, during which participants will receive either depemokimab injections or placebo injections. Some participants will also receive prednisolone tablets or matching placebo tablets as part of their treatment.

Throughout the study, doctors will monitor how often participants experience HES flares, which are periods when symptoms get worse or blood eosinophil counts increase. The medication will be provided in a pre-filled syringe for injection under the skin. Participants will be regularly checked for any changes in their condition and any effects of the treatment.

]]> Study on Mepolizumab for Children and Teens with Hypereosinophilic Syndrome https://clinicaltrials.eu/trial/study-on-mepolizumab-for-children-and-teens-with-hypereosinophilic-syndrome/ Wed, 29 Apr 2026 14:27:50 +0000 https://clinicaltrials.eu/trial/study-on-mepolizumab-for-children-and-teens-with-hypereosinophilic-syndrome/ This clinical trial is focused on studying a condition known as Hypereosinophilic Syndrome (HES), which is a rare disorder where the body produces too many eosinophils, a type of white blood cell. The study is testing a treatment called mepolizumab, which is given as a solution for injection under the skin. Mepolizumab is designed to help reduce the number of eosinophils in the blood, potentially improving symptoms for those with HES.

The purpose of the study is to evaluate how effective and safe mepolizumab is for children and teenagers aged 6 to 17 years who have HES. Participants in the study will receive mepolizumab injections every four weeks over a period of 52 weeks. The study will monitor the frequency of HES flare-ups, which are episodes when symptoms worsen, and will also look at changes in the use of other medications that participants might be taking for HES.

Throughout the study, researchers will collect information on how participants are feeling, including their levels of fatigue, which is a common symptom of HES. The study will also measure the concentration of mepolizumab in the blood at different times to understand how the body processes the medication. This information will help determine the overall effectiveness and safety of mepolizumab for treating HES in young patients.

]]> Study of benralizumab compared to placebo for treatment of patients with Hypereosinophilic Syndrome (HES) https://clinicaltrials.eu/trial/study-on-benralizumab-for-treating-hypereosinophilic-syndrome-in-patients/ Wed, 29 Apr 2026 14:27:38 +0000 https://clinicaltrials.eu/trial/study-on-benralizumab-for-treating-hypereosinophilic-syndrome-in-patients/ This study focuses on patients with Hypereosinophilic Syndrome (HES), a condition where there are persistently high levels of certain white blood cells called eosinophils in the blood, which can cause damage to various organs. The study will test a medication called benralizumab (Fasenra), which is given as an injection under the skin, to see if it can help control HES symptoms and prevent disease flares.

The research aims to determine how effective benralizumab is in delaying or preventing HES flares compared to placebo. During the study, which lasts 24 weeks, participants will receive either benralizumab or placebo through an injection under the skin using a pre-filled syringe. After this initial period, there is an opportunity to continue treatment in an open-label extension phase where all participants receive the active medication.

Throughout the study, doctors will monitor participants’ symptoms, particularly looking for signs of disease worsening or flares. They will also track changes in blood cell counts, fatigue levels, and overall health. The medication being tested is designed to reduce the number of eosinophils in the blood, which may help control the symptoms of HES and prevent organ damage.

]]>